Clinical Trial

Treatment Intensification With Temozolomide in Adults With a Glioblastoma

Study acronym: StrateGlio
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Due to conflicting data on the optimal moment to start TMZ chemotherapy and the impact of prolongation of the adjuvant phase with TMZ, the ANOCEF (Association des Neuro-Oncologues d'Expression Francophone) group proposes this randomized trial comparing an intensified arm (early TMZ and extended adjuvant TMZ until toxicity, progression or patient refusal) versus the classical EORTC regimen as control (RT and concomitant TMZ started 4-6 weeks after surgery followed by a number of adjuvant TMZ cycles strictly limited to 6) for primary GBM adult patients.
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-03-31
notable Primary completion pushed: 2027-02 -> 2027-06 2026-03-31
minor Completion moved earlier: 2028-05-01 -> 2027-06 2026-03-31
Trial Details
NCT Number NCT03663725
Lead Sponsor Centre Oscar Lambret
Collaborators: Association de Neuro-Oncologues d'Expression Francaise, Erasme University Hospital
Conditions Glioblastoma
Enrollment 486 participants
Start Date 2019-03-13
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-03-30